Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-3.49 Insider Own9.92% Shs Outstand3.12M Perf Week2.35%
Market Cap69.20M Forward P/E- EPS next Y-1.69 Insider Trans0.00% Shs Float2.81M Perf Month3.64%
Income-21.93M PEG- EPS next Q-1.00 Inst Own50.54% Short Float0.17% Perf Quarter387.47%
Sales0.00M P/S- EPS this Y37.43% Inst Trans-32.14% Short Ratio0.19 Perf Half Y506.01%
Book/sh10.20 P/B2.17 EPS next Y23.06% ROA-52.67% Short Interest0.00M Perf Year633.34%
Cash/sh12.04 P/C1.84 EPS next 5Y- ROE-61.86% 52W Range2.50 - 22.15 Perf YTD506.01%
Dividend Est.- P/FCF- EPS past 5Y-18.32% ROI-69.00% 52W High0.13% Beta0.15
Dividend TTM- Quick Ratio6.09 Sales past 5Y-20.00% Gross Margin- 52W Low787.20% ATR (14)0.50
Dividend Ex-Date- Current Ratio6.09 EPS Y/Y TTM64.21% Oper. Margin0.00% RSI (14)94.27 Volatility1.45% 1.19%
Employees19 Debt/Eq0.00 Sales Y/Y TTM-100.00% Profit Margin- Recom2.33 Target Price9.56
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q24.16% Payout- Rel Volume0.35 Prev Close22.15
Sales Surprise- EPS Surprise-8.20% Sales Q/Q- EarningsMar 21 BMO Avg Volume25.77K Price22.18
SMA202.65% SMA5074.20% SMA200255.42% Trades Volume9,082 Change0.13%
Date Action Analyst Rating Change Price Target Change
Apr-12-22Downgrade Jefferies Buy → Hold $30 → $1.40
Nov-16-21Downgrade SVB Leerink Outperform → Mkt Perform $20 → $16
Oct-20-21Initiated Craig Hallum Buy $45
Oct-19-21Initiated H.C. Wainwright Buy $50
Mar-01-21Initiated SVB Leerink Outperform $20
Mar-01-21Initiated Raymond James Outperform $33
Mar-01-21Initiated JP Morgan Neutral $17
Mar-01-21Initiated Jefferies Buy $32
Mar-25-24 01:27PM
01:52PM Loading…
Mar-21-24 01:52PM
Jan-08-24 08:00AM
Nov-21-23 08:00AM
Nov-09-23 08:00AM
Oct-23-23 08:00AM
Sep-19-23 08:00AM
Sep-14-23 08:00AM
Aug-09-23 08:00AM
May-31-23 04:15PM
04:15PM Loading…
May-30-23 04:15PM
May-25-23 04:05PM
May-12-23 08:50AM
Mar-23-23 08:00AM
Feb-28-23 05:00PM
Jan-11-23 07:00AM
Jan-05-23 07:05AM
Nov-10-22 08:00AM
Oct-15-22 09:36AM
Sep-06-22 07:00AM
Aug-12-22 06:37PM
Aug-11-22 08:30AM
Aug-03-22 08:00AM
08:00AM Loading…
Jun-21-22 08:00AM
May-13-22 08:28AM
May-12-22 04:05PM
May-11-22 07:32AM
May-08-22 09:00AM
Mar-24-22 04:45PM
Mar-10-22 08:00AM
Feb-04-22 07:23AM
Nov-17-21 08:33AM
Nov-15-21 07:30AM
Nov-11-21 04:05PM
Nov-10-21 08:32AM
Nov-08-21 08:10AM
Nov-02-21 08:28AM
Oct-28-21 07:00AM
Oct-15-21 08:49AM
Oct-11-21 07:00AM
Oct-06-21 07:00AM
Sep-27-21 07:00AM
Sep-20-21 07:00AM
Sep-15-21 07:00AM
Sep-01-21 07:00AM
Aug-26-21 07:00AM
Aug-19-21 03:03PM
Aug-05-21 07:00AM
Jul-22-21 07:00AM
Jun-14-21 05:08PM
May-25-21 07:00AM
May-19-21 07:00AM
May-17-21 09:29AM
May-06-21 04:01PM
May-04-21 08:51AM
Apr-29-21 07:00AM
Apr-26-21 11:56AM
Apr-13-21 07:00AM
Apr-06-21 09:53AM
Mar-04-21 07:00AM
Feb-26-21 06:26PM
Feb-23-21 04:00PM
Feb-05-21 05:26PM
Feb-04-21 05:56PM
Feb-03-21 08:13PM
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of novel, oral, once-daily therapeutics for patients with certain immunology diseases. It offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The firm's preclinical candidates include LABP-73, LABP-66, and LABP-69. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.